Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GUCY2C CAR T cells

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GUCY2C CAR T cells target and bind to GUCY2C-expressing tumor cells, thereby inducing selective toxicity in GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-guanylate cyclase 2C CAR T cells GUCY2C-targeting CAR T cells

anti-GUCY2C CAR T cells

Search NCI's Drug Dictionary